Advertisement
Advertisement

INCY

INCY logo

Incyte Genomics Inc

127.01
USD
Sponsored
-0.99
-0.77%
Sep 04, 10:30 UTC -4
Open

Incyte Genomics Inc Profile

About

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2 inhibitor, approved in the United States for the treatment of patients with polycythemia vera ('PV'),who have had an inadequate response to or are intolerant to hydroxyurea. It is also approved for the treatment of patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-PV MF, and post-essential thrombocythemia MF. The drug is also approved in the United States for treatment of steroid-refractory acute graft-versus-host disease (GVHD) in adult and pediatric patients aged 12 years or older.

Info & Links

CEO

William J. Meury

Headquarters

1801 AUGUSTINE CUT-OFF
WILMINGTON, DE 19803, UNITED STATES

Industry

Medical Biomedical And Genetics

Sector

Medical

Website

www.incyte.com

Auditor

Ernst & Young LLP

Share holders

97

Employees

2,844

Incyte Genomics Inc Statistics

Valuation Measures

Market Capitalization2

25.74B

Enterprise Value

21.79B

Enterprise Value/EBITDA(ttm)

11.61

Price to Earnings Ratio(ttm)

16.23

Price to Sales(ttm)

4.49

Price to Book(mrq)

4.12

Price to Cash(ytd)

20.84

Profitability

Gross Margin(ttm)

92.56%

Operating Margin(ttm)

28.01%

Profit Margin(ttm)

27.43%

Return on Equity(ttm)

29.93%

Return on Invested Capital(ttm)

29.37%

Return on Assets(ttm)

22.88%

Income Statement

Revenue(ttm)

5.82B

Revenue Per Share(ttm)

28.71

Gross Profit(ttm)

5.39B

EBITDA(ttm)3

1.88B

Net Income Available to Common(ttm)

1.61B

Diluted EPS(ttm)

7.85

Share Statistics

Beta (5Y Monthly)

0.77

52-Week Change

46.06%

S&P 500 52-Week Change

19.90%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding1

202.70M

Dividend Yield

0.00%

Float4

169.86M

% Held by Insiders

16.20%

% Held by Institutions

96.97%

Balance Sheet

Total Cash(mrq)

4.54B

Total Cash Per Share(mrq)

22.38

Total Debt(mrq)

32.68M

Total Debt/Equity(mrq)

0.52%

Current Ratio(mrq)

4.59%

Quick Ratio(mrq)

4.51%

Book Value Per Share(mrq)

31.57

Cash Flow

Operating Cash Flow Per Share(ytd)

4.21

Free Cash Flow(ytd)

854.40M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

  • 1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
  • 2 Market Cap is calculated using total shares outstanding and the most recent share price.
  • 3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
  • 4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Advertisement